Melania Capitani, Postdoctoral Fellow

Melania-Capitani

 

Brief Biography:

I performed my Master thesis and my PhD at the University of Camerino (Italy), where I mainly focused on the development of DNA vaccines for cancer and other chronic diseases. My PhD project was partially performed at Vaxine LTD-Flinders University-Australia and was based on the development of a DNA-based adjuvant to potentiate the response of DNA vaccines in mouse models.

After my first PostDoc in Italy, I took the opportunity to apply my Molecular Biology background in the context of IBD at the Uhlig Lab, where I am currently doing my post-Doc.

 

Research Interests:

Investigating the anti-bacterial response in macrophages from patients with monogenic disorders.

Current project:

Generation of iPS derived macrophage knockouts for genes involved in the onset of monogenic IBD using CRISPR/Cas technology. This will elucidate the molecular mechanisms behind these disorders and aid in finding potential therapeutic approaches.

Investigation of molecular mechanisms behind DNAse2 deficiency. 

Publications:

NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease.Schwerd T, Bryant RV, Pandey S, Capitani M, et al.  Mucosal Immunol. 2017 Nov 1. doi: 10.1038/mi.2017.74.

Permethrin pesticide induces NURR1 up-regulation in dopaminergic cell line: Is the pro-oxidant effect involved in toxicant-neuronal damage?
Bordoni L, Fedeli D, Nasuti C, Capitani M, Fiorini D, Gabbianelli R. Comp Biochem Physiol C Toxicol Pharmacol. 2017 Oct;201:51-57.

A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis.
Schwerd T, Twigg SRF, Aschenbrenner D, Manrique S, Miller KA, Taylor IB, Capitani M, et al.  J Exp Med. 2017 Sep 4;214(9):2547-2562. 

INF-γ encoding plasmid administration triggers bone loss and disrupts bone marrow microenvironment.                               Agas D, Gusmão Silva G, Laus F, Marchegiani A, Capitani M, et al. J Endocrinol. 2017 Feb;232(2):309-321. Epub 2016 Dec 1.

In vivo biocompatibility of p(HPMAm-lac)-PEG hydrogels hybridized with hyaluronan.
Sabbieti MG, Dubbini A, Laus F, Paggi E, Marchegiani A, Capitani M, Marchetti L, Dini F, Vermonden T, Di Martino P, Agas D, Censi R.J Tissue Eng Regen Med. 2016 Oct 24. doi: 10.1002/term.2207.

Administration of DNA Plasmid Coding Protein Aggregating Domain Induces Inflammatory Bone Loss. Agas D, Concetti F, Capitani M, Lacava G, Concetti A, Marchetti L, Laus F, Marchegiani A, Azevedo V,Sabbieti MG, Venanzi FM. Curr Gene Ther. 2016;16(2):144-52.

Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent.
Sabbieti  MG, Agas D, Capitani M, Marchetti L, Concetti A, Vullo C, Catone G, Gabai V., Shifrin V, Sherman MY,  Shneider A, Venanzi FM. Oncotarget Journal, December 2014

Plasmids encoding protein aggregation-inducing domains  act as adjuvants for DNA vaccination.
Capitani M, Saade F, Havas KM, Angeletti M, Concetti F, Agas D, Sabbieti MG, Concetti A, Venanzi FM, Petrovsky N. Curr Gene Ther 2014.

The dual face of parathyroid hormone and prostaglandins in osteoimmunology.
Sabbieti MG, Marchetti L, Capitani M, Agas D. Am j Physiol Endocrinol Metab. 2013 set 17. (Review)

The functional VNTR MNS16A of TERT gene is associated with humoral longevity in a population of Central Italy.
Concetti F, Di Pietro F, Carpi FM, Dato S, Capitani M, Nabissi M, Santoni G, Mignini F, Passarino G, Lucarini N, Napolioni V. Exp. Gerontol.  2013, 48 (6) :587-92.

Co-Expression of   Flt-3 Ligand Gene Ablates Tumor Immunity Elicited by HER-2/new DNA Vaccine.
Venanzi FM, Barucca A, Havas KM, Capitani M, Provinciali M, Scotti S, Concetti A. Vaccine. 28(22):3841-3847.

Recombinant DNA Technology for Melanoma Immunotherapy: Anti-Id DNA Vaccines Targeting High Molecular Weight Melanoma-Associated Antigen.  
Barucca A, Capitani M, Cesca M, Tomassoni D, Kazmi U, Concetti F, Vincenzetti L, Concetti A,  Venanzi FM. Mol Biotechnol. 2014.